Domains featuring this topic
Explore the domains where this topic appears.
Advancing CAR T Cell Therapy for Brain Tumors: Overcoming Barriers to Efficacy
Gladstone-UCSF Institute of Genomic Immunology Seminar by Christine Brown, PhD (Deputy Director, T Cell Therapeutics Research Laboratories) on developing and refining redirected CAR T cells for malignant brain tumors, including glioblastoma, tumor heterogeneity, immunosuppressive microenvironments, delivery routes, and manufacturing.
Postdoctoral Research Associate
Wellcome Trust-funded post at Barts Cancer Institute developing gamma delta T cell immunotherapy strategies for liver cancer using advanced 3D patient-derived models, with opportunities to co-supervise MSc/PhD students.
Aging promotes reactivation from metastatic melanoma dormancy
How does the primary tumor imprint a dormancy signature in disseminated tumor cells?
T cells specific for alpha-myosin drive immunotherapy-related myocarditis
CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor
When to stop immune checkpoint inhibitor for malignant melanoma? Challenges in emulating target trials
Observational data have become a popular source of evidence for causal effects when no randomized controlled trial exists, or to supplement information provided by those. In practice, a wide range of designs and analytical choices exist, and one recent approach relies on the target trial emulation framework. This framework is particularly well suited to mimic what could be obtained in a specific randomized controlled trial, while avoiding time-related selection biases. In this abstract, we present how this framework could be useful to emulate trials in malignant melanoma, and the challenges faced when planning such a study using longitudinal observational data from a cohort study. More specifically, two questions are envisaged: duration of immune checkpoint inhibitors, and trials comparing treatment strategies for BRAF V600-mutant patients (targeted therapy as 1st line, followed by immunotherapy as 2nd line, vs. immunotherapy as 2nd line followed by targeted therapy as 1st line). Using data from 1027 participants to the MELBASE cohort, we detail the results for the emulation of a trial where immune checkpoint inhibitor would be stopped at 6 months vs. continued, in patients in response or with stable disease.
Robotic mapping and generative modelling of cytokine response
We have developed a robotic platform allowing us to monitor cytokines dynamics (including IL-2, IFN-g, TNF, IL-6) of immune cells in vitro, with unprecedented resolution. To understand the complex emerging dynamics, we use interpretable machine learning techniques to build a generative model of cytokine response. We discover that, surprisingly, immune activity is encoded into one global parameter, encoding ligand antigenic properties and to a less extent ligand quantity. Based on this we build a simple interpretable model which can fully explain the broad variability of cytokines dynamics. We validate our approach using different lines of cells and different ligands. Two processes are identified, connected to timing and intensity of cytokine response, which we successfully modulate using drugs or by changing conditions such as initial T cell numbers. Our work reveals a simple "cytokine code", which can be used to better understand immune response in different contexts including immunotherapy. More generally, it reveals how robotic platforms and machine learning can be leveraged to build and validate systems biology models.